decad
pass
sinc
discoveri
angiotensinconvert
enzym
compon
ang
ma
counterregulatori
axi
renin
angiotensin
system
ra
consid
endogen
regul
vasoconstrict
prolif
fibrot
proinflammatori
effect
aceang
iiangiotensin
ii
type
receptor
r
axi
anim
clinic
studi
emerg
defin
role
pulmonari
arteri
hypertens
pah
scientif
evid
support
concept
maintain
ra
balanc
play
protect
role
pah
activ
pulmonari
could
influenc
pathogenesi
pah
serv
novel
therapeut
target
pah
current
therapeut
strategi
intervent
limit
success
pah
remain
fatal
diseas
thu
research
establish
novel
therapeut
potenti
defin
mechan
ma
counterregulatori
axi
pah
need
angiotensin
ang
convert
enzym
implic
number
physiolog
pathophysiolog
process
novel
homologu
ace
compon
counterregulatori
axi
ace
monocarboxypeptidas
gener
ang
anoth
compon
reninangiotensin
system
ra
attenu
vasoconstrict
prolif
fibrot
inflammatori
effect
ang
ii
cleav
singl
residu
substrat
ang
gener
ang
singl
residu
anoth
prefer
substrat
ang
ii
gener
ang
also
cleav
peptid
substrat
desargbradykinin
neurotensin
kinetensin
play
pertin
role
vasoprotect
axi
ra
ma
counterbal
vasoconstrict
prolif
fibrot
action
aceang
iiang
ii
type
receptor
r
axi
abundantli
express
mani
cell
type
lung
clara
cell
type
ii
alveolar
epitheli
cell
macrophag
endothelium
smooth
muscl
cell
smc
blood
vessel
bronchial
epithelia
ra
compon
wide
express
lung
activ
pulmonari
could
influenc
pathogenesi
lung
injuri
serv
novel
therapeut
target
pulmonari
arteri
hypertens
pah
pah
chronic
diseas
divers
etiolog
despit
modern
therapeut
advanc
world
health
organ
function
class
whofc
estim
median
surviv
month
whofc
iv
year
whofc
iii
year
whofc
iii
although
target
treatment
pleiotrop
drug
approach
novel
progenitorcel
therapi
provid
symptomat
relief
prolong
surviv
pah
remain
fatal
diseas
cure
without
proper
therapi
chronic
vasoconstrict
inflamm
situ
thrombosi
promot
increas
pulmonari
vascular
remodel
pvr
clinic
pah
character
increas
mean
pulmonari
arteri
pressur
mm
hg
rest
persist
elev
pulmonari
vascular
resist
lead
main
caus
death
patient
rightsid
heart
failur
pah
herit
predispos
genet
environment
risk
factor
may
lead
imbal
counterregulatori
mechan
associ
pulmonari
vascular
remodel
vasoconstrictionvasodilat
proliferationantiprolifer
prothrombogen
antithrombogen
imbal
initi
cascad
pathophysiolog
event
lung
lead
pah
exact
pathogenesi
diseas
still
unknown
base
upon
concept
homeostat
imbal
multifactori
pathobiolog
mainstay
pah
treatment
includ
vasodil
anticoagul
calcium
channel
blocker
endothelin
receptor
antagonist
reninangiotensin
system
ra
wellrecogn
player
endotheli
dysfunct
vascular
remodel
precis
involv
system
member
lung
pathophysiolog
pah
remain
elus
thu
discoveri
emerg
counterregulatori
concept
ra
great
signific
aceang
iiat
r
axi
promot
vasoconstrict
prolifer
fibrosi
wherea
ma
axi
protect
lung
ma
axi
intrins
induc
vasoprotect
action
counterregul
aceang
iiat
r
axi
review
focus
vasoprotect
axi
ra
potenti
target
therapeut
intervent
pah
conceptu
breakthrough
urgent
need
develop
novel
strategi
therapeut
intervent
manag
pah
research
establish
role
lung
pathophysiolog
emerg
pah
chronic
diseas
divers
etiolog
clinic
character
increas
pulmonari
vascular
resist
tabl
outlin
current
classif
form
pulmonari
hypertens
ph
genet
mutat
influenc
pah
develop
year
mutat
gene
encod
bone
morphogenet
protein
receptor
type
ii
bmprii
transform
growth
factor
tgf
superfamili
receptor
identifi
primari
genet
mutat
patient
pah
pah
patient
often
character
remodel
small
distal
pulmonari
arteri
result
medial
hypertrophi
intim
prolifer
adventiti
thicken
moder
inflammatori
infiltr
plexiform
lesion
thrombot
lesion
remodel
caus
increas
pulmonari
vascular
resist
result
mean
pulmonari
arteri
pressur
greater
mm
hg
rest
persist
elev
pulmonari
vascular
resist
lead
right
heart
failur
death
pah
consequ
vascular
effector
imbal
perturb
homeostasi
vasoconstrictor
vasodil
growth
inhibitor
mitogen
factor
antithrombot
prothrombot
factor
result
find
vasodil
anticoagul
antiplatelet
antiinflammatori
vascular
remodel
therapi
use
pah
treatment
current
intervent
strategi
life
expect
adult
idiopath
pah
less
year
diagnosi
children
less
month
complex
strategi
treat
pah
patient
includ
support
specif
drug
therapi
specif
drug
therapi
often
fall
three
categori
vasodil
calcium
channel
blocker
endothelin
receptor
antagonist
latest
clinic
trial
strateg
target
remodel
includ
test
antiprolif
drug
advanc
human
pah
clinic
anim
data
suggest
intervent
strategi
attenu
action
aceang
iiat
r
axi
ie
angiotensin
receptor
blocker
andor
ace
inhibitor
therapi
activ
ma
axi
ie
activ
viral
transfer
effect
attenu
prevent
maladapt
vascular
remodel
associ
pah
limit
angii
bioactiv
remain
cornerston
cardiovascular
therapeut
plausibl
approach
may
valid
pulmonari
diseas
pulmonari
vascular
fibrosi
hypertrophi
vascular
smooth
muscl
migrat
regress
thu
discoveri
role
lung
pathophysiolog
great
import
initi
discov
receptor
sever
acut
respiratori
syndrom
sar
coronaviru
sequenc
homolog
ace
research
commun
began
determin
local
studi
role
model
system
type
transmembran
protein
contain
singl
metalloproteinas
activ
site
local
human
heart
kidney
coronari
arteri
arteriol
vasa
vasorum
testi
gastrointestin
tract
lung
abundantli
express
mani
cell
type
lung
clara
cell
type
ii
alveolar
epitheli
cell
macrophag
endothelium
smc
bronchial
epithelia
local
endotheli
cell
express
enhanc
wall
newli
muscular
pulmonari
arteri
data
illustr
like
ace
local
lung
vasculatur
specif
endothelium
thu
exist
potenti
therapeut
target
literatur
also
strongli
support
ra
imbal
pulmonari
diseas
lung
injuri
limit
vasoprolif
fibrot
hypertroph
action
ra
lung
injuri
anim
human
pulmonari
studi
reveal
ra
imbal
may
play
import
role
pulmonari
diseas
progress
three
differ
model
acut
respiratori
distress
syndrom
ard
knockout
mice
sever
lung
diseas
elev
serum
tissu
ang
ii
level
increas
collagen
deposit
loss
ace
acut
lung
injuri
lead
leaki
pulmonari
blood
vessel
receptor
stimul
lung
injuri
model
induc
acid
aspir
sepsi
delet
worsen
injuri
aorta
mice
exhibit
impair
endotheliumdepend
vasodil
ra
imbal
support
literatur
reveal
sever
lung
failur
knockout
background
rescu
ace
inactiv
ra
imbal
also
evid
anim
model
ph
bleomycininduc
ph
pulmonari
fibrosi
associ
decreas
activ
upregul
respons
hypoxia
illustr
protect
effect
sever
acut
lung
failur
activ
key
transcript
factor
hypoxia
hif
increas
ace
decreas
tracheal
inject
prevent
partial
revers
ph
monocrotalin
mct
model
ph
target
may
addit
benefici
effect
unlik
blockad
ace
rs
target
ph
novel
strategi
fig
multifunct
enzym
pleiotrop
effect
give
protect
degrad
ang
ii
also
produc
vasodilatori
peptid
ang
anim
model
literatur
also
strongli
support
pharmacolog
treatment
lung
diseas
pvr
occur
pah
studi
prevent
limit
regress
pvr
import
progress
field
sepsisinduc
knockout
model
acut
lung
injuri
treatment
recombin
human
protein
provid
direct
protect
studi
also
suggest
ang
ii
ace
receptor
promot
lung
injuri
wherea
receptor
protect
lung
injuri
overexpress
improv
endotheli
cell
migrat
tube
format
demonstr
mcttreat
mice
pulmonari
overexpress
via
lentivir
vector
prevent
revers
increas
right
ventricular
systol
pressur
significantli
attenu
partial
revers
muscular
pulmonari
vessel
increas
r
r
mrna
ratio
studi
reveal
activ
endogen
xnt
ethylamino
hydroxymethyl
sulfonyl
oxi
prevent
pulmonari
vascular
remodel
ph
develop
fig
target
ang
ma
axi
prevent
revers
pulmonari
vascular
patholog
pulmonari
arteri
hypertens
aceangiotensinconvert
enzym
ang
iiangiotensin
ii
rangiotensin
ii
type
receptor
rangiotensin
ii
type
receptor
bmpriibon
morphogenet
protein
receptor
type
ii
signalregul
protein
kinas
nonitr
oxid
growth
factor
ment
xnt
revers
cardiac
hypertrophi
ventricular
fibrosi
renal
interstiti
fibrosi
prevent
increas
right
ventricular
systol
pressur
rvsp
right
ventricular
hypertrophi
attenu
vascular
wall
thicken
pulmonari
fibrosi
xnt
decreas
proinflammatori
cytokin
level
increas
antiinflammatori
cytokin
level
increas
activ
xnt
advers
effect
system
blood
pressur
effect
inhibit
ang
antagonist
demonstr
may
produc
benefici
effect
via
ang
interestingli
overexpress
smooth
muscl
spontan
hypertens
stroke
prone
rat
shrsp
result
increas
aortic
activ
ang
ang
ii
improv
vascular
function
ma
agonist
confer
endotheliumdepend
relax
effect
chronic
sustain
imbal
favor
aceang
iiat
r
axi
may
promot
progress
lung
diseas
believ
benefici
effect
system
involv
shift
vasoconstrict
prolif
fibrot
axe
vasoprotect
axi
ra
thu
target
ra
ph
revisit
therapeut
target
unlik
ace
inhibitor
angiotensinreceptor
blocker
arb
endogen
regul
ra
therapi
ace
inhibitor
arb
indirectli
increas
ang
activ
would
directli
increas
enzym
promot
benefici
effect
like
ace
inhibitor
arb
therapi
activ
attenu
remodel
fibrosi
affect
vascular
relax
properti
endothelium
ra
intervent
studi
ph
inconclus
role
ma
axi
activ
ph
confirm
clinic
trial
controversi
ace
inhibitorarb
therapi
evid
benchsid
pharmacolog
inhibit
ra
translat
bedsid
treatment
patient
hypertens
congest
heart
failur
left
ventricular
dysfunct
pulmonari
system
edema
diabet
nephropathi
cirrhosi
liver
scleroderma
although
evid
clinic
anim
studi
support
content
ra
involv
develop
progress
pah
use
ace
inhibitor
pah
remain
controversi
tabl
enalapril
anoth
ace
inhibitor
given
concomitantli
mct
chronic
pah
rat
model
fed
highcholesterol
diet
therapeut
intervent
attenu
develop
pah
preserv
express
endotheli
nitric
oxid
synthas
eno
demonstr
role
ra
develop
pah
hypox
rat
model
pah
dose
addit
block
ace
angiotensin
receptor
aceang
iiat
r
axi
inhibitor
increas
ang
express
level
rat
human
patient
primari
ph
higher
cardiac
activ
ang
level
provid
cardioprotect
patient
pulmonari
fibrosi
express
decreas
find
may
indic
ace
inhibit
may
less
effect
scleroderma
hypox
ph
may
effect
attenu
remodel
given
earlier
diseas
state
addit
regress
remodel
ace
inhibitor
lower
system
blood
pressur
therefor
may
benefici
ph
patient
right
heart
failur
limit
amount
evid
support
mechanist
role
ma
axi
complet
understand
ma
axi
protect
lung
ph
literatur
establish
ma
receptor
g
proteincoupl
receptor
activ
ang
counteract
action
aceang
iiat
r
axi
ra
system
yet
mechan
involv
still
unclear
like
downstream
target
ang
ma
demonstr
impact
endotheli
function
ma
knockout
mice
exhibit
impair
endotheli
function
decreas
eno
cardiac
myocyt
masdefici
mice
ma
defici
impair
ang
signal
recent
articl
brainselect
overexpress
attenu
neurogen
hypertens
possibl
ma
r
upregul
gallagh
et
al
report
ang
prevent
ang
iimedi
reduct
mrna
block
ang
receptor
antagonist
dala
ang
mitogenactiv
protein
map
kinas
kinas
inhibitor
also
first
demonstr
vascular
smc
map
kinasephosphatas
pathway
regul
maintain
balanc
ang
ii
ang
ang
function
prostaglandin
antifibrot
antioxid
properti
gwathmey
et
al
first
demonstr
ang
promot
proteolyt
convers
ang
ii
within
nucleu
potenti
endogen
modul
reactiv
oxygen
speci
ro
product
wang
et
al
demonstr
circul
ang
stimul
cardiac
endotheli
progenitor
cell
epc
prolifer
benefit
myocardi
infarct
tallant
et
al
suggest
ang
inhibit
vascular
growth
releas
prostacyclin
prostacyclinmedi
product
cyclic
adenosin
monophosph
camp
activ
campdepend
protein
kinas
attenu
map
kinas
activ
mechanist
studi
establish
ma
receptor
axi
compon
exist
within
nucleu
everi
level
vascular
wall
pois
initi
sustain
vasoprotect
effect
ang
ii
promot
growth
prolifer
fibrosi
upregul
ace
downregul
superfamili
encompass
larg
number
growth
factor
ligand
activin
inhibin
bone
morphogenet
protein
bmp
bmp
involv
vascular
integr
control
vascular
cell
prolifer
bmp
isoform
control
endotheli
cell
smc
prolifer
apoptosi
extracellular
matrix
ecm
secret
deposit
bmprii
plasma
membran
protein
express
decreas
pulmonari
endotheli
cell
herit
sporad
pah
bmprii
local
endothelium
vascular
smc
small
pulmonari
arteri
signal
transduct
studi
reveal
bmp
signal
mediat
type
ii
receptor
downstream
mediat
form
complex
transloc
nucleu
function
bmprii
mediat
growth
suppress
apoptosi
vasculatur
thu
loss
bmprii
function
may
lead
vasculopathi
evid
pah
late
cultur
epc
idiopath
pah
patient
bmprii
mutat
show
hyperprolif
phenotyp
impair
abil
form
vascular
network
signal
control
number
function
prolifer
migrat
differenti
apoptosi
ecm
deposit
secret
mutat
gene
encod
either
bmp
signal
system
associ
pah
research
suggest
abnorm
bmp
signal
imbalanc
pah
thu
bmp
appear
play
oppos
role
fig
mainten
growth
pulmonari
arteri
smc
endotheli
cell
studi
suggest
inhibitori
effect
bmp
signal
pulmonari
arteri
smc
cell
pah
patient
resist
antiprolif
effect
bmp
gain
prolifer
bmprii
loss
growth
suppress
inabl
promot
vascular
smc
apoptosi
may
promot
pah
develop
hong
et
al
reveal
increas
rvsp
increas
muscular
knockout
mice
incomplet
penetr
reynold
et
al
demonstr
overexpress
bmprii
hypox
rat
model
protect
pah
develop
bmprii
heterozyg
null
mice
sever
hypox
ph
decreas
eno
express
activ
signal
modul
mct
rat
model
result
controversi
studi
suggest
mct
inhibit
signal
other
suggest
mct
enhanc
signal
inhibit
activinlik
kinas
type
receptor
prevent
revers
pah
hypox
mct
model
bmprii
mrna
protein
express
reduc
increas
signal
mct
model
hypox
model
increas
signal
rvsp
vascular
remodel
mct
model
attenu
inhibit
reduct
bmprii
signal
due
genet
environment
cue
may
caus
bmprii
signal
fall
threshold
trigger
pah
vasculopathi
imbal
signal
promot
pah
develop
progress
sinc
discoveri
investig
sar
coronaviru
infect
cardiovascular
renal
central
nervou
pulmonari
system
benefit
overexpress
activ
pah
support
use
proof
concept
preclin
trial
interest
discov
link
bmprii
ma
axi
regardless
diseas
etiolog
remodel
consist
intim
fibrosi
increas
medial
thick
pulmonari
arteriolar
occlus
plexiform
lesion
shown
prevent
fibrosi
compon
pvr
therefor
therapi
may
effect
prevent
diseas
progress
form
ph
perturb
bmp
signal
increas
missens
mutat
knowledg
differ
diseas
sever
differ
bmprii
mutat
critic
therapeut
design
cilostazol
phosphodiesteras
iii
inhibitor
offer
synergist
benefit
amelior
mctinduc
pah
rat
rosuvastatin
blunt
increas
rvsp
reduc
mean
arteri
pressur
rat
hypoxiainduc
ph
model
transplant
cultur
earli
epc
fail
revers
vascular
remodel
chang
pulmonari
hemodynam
intraven
administr
bone
marrow
cell
fail
prevent
increas
rvsp
arteri
muscular
yet
raoul
et
al
demonstr
infus
cell
effect
prevent
mctinduc
ph
zhao
et
al
also
show
bone
marrowderiv
endotheliallik
progenitor
cell
effect
prevent
revers
mctinduc
ph
pulmonari
vascular
remodel
encompass
endotheli
dysfunct
fibroblast
smc
activ
crosstalk
cell
within
vascular
wall
recruit
circul
progenitor
cell
may
potenti
therapeut
target
addit
target
activ
overexpress
literatur
illustr
possibl
novel
target
intervent
phosphodiesteras
inhibitor
statin
larginin
antiplatelet
agent
serotonin
inhibitor
agent
alter
ion
channel
function
gene
therapi
elastas
inhibitor
antiprolif
heparin
tyrosin
kinas
inhibitor
bone
marrowderiv
endotheli
progenitor
cell
treatment
aceang
iiat
r
axi
ra
implic
pah
yet
intervent
studi
use
ace
inhibitor
arb
remain
controversi
evid
target
ma
axi
ra
support
idea
axi
antagon
prolif
fibrot
hypertroph
effect
aceang
iiat
r
axi
effort
advanc
research
effort
pah
therapi
must
consid
efficaci
activ
clinic
trial
use
subpressor
dose
ace
inhibitor
arb
clinic
trial
larger
clinic
trial
efficaci
ace
inhibitor
regress
establish
lesion
compar
new
lesion
time
intervent
identif
bone
marrow
cell
type
treat
pah
develop
anim
model
reflect
human
pah
need
novel
strateg
intervent
pah
chronic
fatal
diseas
current
therapi
address
vasoconstrictor
imbal
endotheli
dysfunct
vasodil
therapi
yet
improv
patient
surviv
unlik
epoprostenol
prostacyclin
analogu
potent
vasodil
pah
therapi
improv
surviv
therefor
new
therapi
target
pvr
emerg
increas
evid
support
concept
imbal
variou
compon
ra
anim
human
trial
demonstr
imbal
favor
aceang
iiat
r
axi
action
promot
prolifer
fibrosi
growth
current
consensu
efficaci
therapeut
pah
strategi
ace
arb
human
anim
model
yet
benefit
overexpress
activ
lung
consist
pah
overexpress
activ
exert
effect
via
ma
axi
limit
detriment
action
aceang
iiat
r
axi
play
protect
role
ph
exact
mechan
benefit
remain
elus
benefit
prevent
revers
studi
anim
model
clear
thu
activ
novel
effect
strategi
pah
must
consid
disclosur
potenti
conflict
interest
relev
articl
report
